News | Coronavirus (COVID-19) | January 08, 2021

The FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests

The FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests

Getty Images


January 8, 2021 — The U.S. Food and Drug Administration is alerting clinical laboratory staff and healthcare providers that the FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests, and that false negative results can occur with any molecular test for the detection of SARS-CoV-2 if a mutation occurs in the part of the virus’s genome assessed by that test. The SARS-CoV-2 virus can mutate over time, like all viruses, resulting in genetic variation in the population of circulating viral strains, as seen with the B.1.1.7 variant. The FDA is taking additional actions to ensure authorized tests remain accurate by working with test developers and conducting ongoing data analysis to evaluate all currently authorized molecular tests. The FDA believes the risk that these mutations will impact overall testing accuracy is low.

“The FDA will continue to monitor SARS-CoV-2 genetic viral variants to ensure authorized tests continue to provide accurate results for patients,” said FDA Commissioner Stephen M. Hahn, M.D. “While these efforts continue, we are working with authorized test developers and reviewing incoming data to ensure that health care providers and clinical staff can quickly and accurately diagnose patients infected with SARS-CoV-2, including those with emerging genetic variants. At this time, we believe the data suggests that the currently authorized COVID-19 vaccines may still be effective against this strain. The FDA will continue to keep health care providers and the public informed of any new information as it becomes available.”

The FDA has been monitoring SARS-CoV-2 viral mutations, and potential impact on testing, throughout the pandemic. The presence of SARS-CoV-2 genetic variants in a patient sample can potentially change the performance of a SARS-CoV-2 test. Tests that rely on the detection of multiple regions of the genome may be less impacted by genetic variation in the SARS-CoV-2 genome than tests that rely on detection of only a single region.

Three currently authorized molecular tests, MesaBiotech AcculaTaqPath COVID-19 Combo Kit, and Linea COVID-19 Assay Kit, may be impacted by genetic variants of SARS-CoV-2, but the impact does not appear to be significant. Importantly, the detection pattern that appears with the TaqPath and Linea diagnostic tests when certain genetic variants are present may help with early identification of new variants in patients to reduce further spread of infection. The recently identified B.1.1.7 variant has been associated with an increased risk of transmission, therefore early identification of this variant in patients may help reduce further spread of infection.

The FDA has reminded clinical laboratory staff and health care providers about the risk of false negative results with all laboratory tests, including molecular tests. Laboratories should expect some false results to occur even when very accurate SARS-CoV-2 tests are used. Today’s announcement also provides important information and recommendations for clinical laboratory staff and health care providers who use molecular tests for the detection of SARS-CoV-2.

The FDA will continue to communicate with the public as it has additional information to share. The FDA encourages stakeholders to report any adverse events or suspected adverse events experienced with molecular tests for detection of SARS-CoV-2. Voluntary reports can be submitted through MedWatch, the FDA Safety Information and Adverse Event Reporting program. Health care personnel and clinical laboratory staff employed by facilities that are performing COVID-19 testing should follow the reporting requirements for authorized laboratories as specified in the test’s Emergency Use Authorization. Prompt reporting of adverse events can help the FDA identify and better understand the risks associated with medical devices.

For more information: www.fda.gov

Related Radiology Coronavirus Coverage:

COVID-19 Genetic PCR Tests Give False Negative Results if Used Too Early

How Does COVID-19 Appear in the Lungs?

CT Provides Best Diagnosis for Novel Coronavirus (COVID-19)

CT Imaging of the 2019 Novel Coronavirus (2019-nCoV) Pneumonia

Radiologists Describe Coronavirus CT Imaging Features

Chest X-rays in the ER Can Help Predict Severity of COVID-19 in Younger Patients 

Radiology Lessons for Coronavirus From the SARS and MERS Epidemics 

Lungs of Deceased COVID-19 Patients Show Distinctive Features

Study Looks at CT Findings of COVID-19 Through Recovery

Chest CT Findings of Patients Infected With Novel Coronavirus 2019-nCoV Pneumonia

ACR Recommendations for the Use of Chest Radiography and CT for Suspected COVID-19 Case

New CT Scoring Criteria for Timely Diagnosis, Treatment of Coronavirus Disease

New Study Looks at Post-COVID-19 Emerging Disease in Children

New Research Finds Chest X-ray Not Reliable Diagnostic Tool for COVID-19

Radiology Publishes First Case of COVID-19 Encephalopathy

How COVID-19 Affects the Brain in Neuroimaging

How Radiologists are Analyzing the 2019-nCoV Coronavirus Pneumonia Epidemic 

New Research Advocates for Chest CT in COVID-19 Diagnosis

Shortage of PPE Due to COVID-19 Driving Innovation by RT in The Philippines

Chest CT Can Distinguish Negative From Positive Lab Results for COVID-19

Artificial Intelligence Assisted Radiology Technologies Aid COVID-19 Fight in China

Mount Sinai Physicians the First in U.S. Analyzing Lung Disease in Coronavirus Patients from China

Related Content

News | Artificial Intelligence

August 18, 2022 — Covera Health, Inc., a leading diagnostic intelligence company, and Nuance Communications, Inc., today ...

Time August 18, 2022
arrow
News | Teleradiology

August 17, 2022 — In a study published today in the Journal of General Internal Medicine, researchers at the Icahn ...

Time August 17, 2022
arrow
News | X-Ray

August 17, 2022 — The Institute of Human Virology in Nigeria (IHVN) has announced their partnership with Fujifilm, the ...

Time August 17, 2022
arrow
News | SNMMI

August 16, 2022 — Mike Crosby of San Diego, California, has been elected to a two-year term as vice chair of the Patient ...

Time August 16, 2022
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Did you know that Imaging Technology News (ITN) maintains more than 40 comparison charts of product specifications from ...

Time August 12, 2022
arrow
News | ASTRO

August 12, 2022 — The American Society for Radiation Oncology (ASTRO) today expressed its support for President Joseph R ...

Time August 12, 2022
arrow
News | Radiology Education

August 11, 2022 — After a three-year break, this spring featured the return of the anticipated Canon Roadshow Events ...

Time August 11, 2022
arrow
News | Computed Tomography (CT)

August 11, 2022 — For the first time, researchers successfully captured CT images of an entire woolly mammoth tusk ...

Time August 11, 2022
arrow
News | RSNA

August 12, 2022 — Registration is now open for The Radiological Society of North American’s (RSNA) 2022 Conference ...

Time August 11, 2022
arrow
News | Radiology Imaging

August 11, 2022 — Bracco Imaging S.p.A. has announced the renewal of the “Bracco Fellowships” initiative, in partnership ...

Time August 11, 2022
arrow
Subscribe Now